De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
TG Therapeutics Beheer
Beheer criteriumcontroles 3/4
De CEO TG Therapeutics' is Mike Weiss, benoemd in Dec2011, heeft een ambtstermijn van 12.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 15.84M, bestaande uit 5.5% salaris en 94.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 5.72% van de aandelen van het bedrijf, ter waarde $ 191.82M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 12.8 jaar en 10.9 jaar.
Belangrijke informatie
Mike Weiss
Algemeen directeur
US$15.8m
Totale compensatie
| Percentage CEO-salaris | 5.5% |
| Dienstverband CEO | 12.8yrs |
| Eigendom CEO | 5.7% |
| Management gemiddelde ambtstermijn | 12.8yrs |
| Gemiddelde ambtstermijn bestuur | 10.9yrs |
Recente managementupdates
Recent updates
TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry
Sep 01
Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 09TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
Aug 07TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05TG Therapeutics And Ublituximab: From Icing To Lifeline
Jul 08Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jun 06Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$96m |
| Mar 31 2024 | n/a | n/a | US$41m |
| Dec 31 2023 | US$16m | US$875k | US$13m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$176m |
| Mar 31 2023 | n/a | n/a | -US$169m |
| Dec 31 2022 | US$10m | US$875k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$239m |
| Jun 30 2022 | n/a | n/a | -US$288m |
| Mar 31 2022 | n/a | n/a | -US$326m |
| Dec 31 2021 | US$43m | US$1m | -US$348m |
| Sep 30 2021 | n/a | n/a | -US$343m |
| Jun 30 2021 | n/a | n/a | -US$345m |
| Mar 31 2021 | n/a | n/a | -US$319m |
| Dec 31 2020 | US$32m | US$1m | -US$279m |
| Sep 30 2020 | n/a | n/a | -US$231m |
| Jun 30 2020 | n/a | n/a | -US$206m |
| Mar 31 2020 | n/a | n/a | -US$189m |
| Dec 31 2019 | US$13m | US$637k | -US$173m |
| Sep 30 2019 | n/a | n/a | -US$187m |
| Jun 30 2019 | n/a | n/a | -US$159m |
| Mar 31 2019 | n/a | n/a | -US$167m |
| Dec 31 2018 | US$14m | US$656k | -US$173m |
| Sep 30 2018 | n/a | n/a | -US$150m |
| Jun 30 2018 | n/a | n/a | -US$148m |
| Mar 31 2018 | n/a | n/a | -US$132m |
| Dec 31 2017 | US$10m | US$525k | -US$118m |
Compensatie versus markt: De totale vergoeding ($USD 15.84M ) Mike } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.75M ).
Compensatie versus inkomsten: De vergoeding van Mike is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Mike Weiss (58 yo)
12.8yrs
Tenure
US$15,837,559
Compensatie
Mr. Michael S. Weiss, Esq. J.D. also known as Mike, serves as Director of Urica Therapeutics, Inc. He has been an Executive Chairman of Mustang Bio, Inc. since January 2017 and served as its Interim Presid...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 12.8yrs | US$15.84m | 5.72% $ 200.9m | |
| CFO, Corporate Secretary & Treasurer | 12.8yrs | US$1.87m | 0.48% $ 16.7m | |
| Senior Vice President of Corporate Communications | no data | geen gegevens | geen gegevens | |
| Chief Commercialization Officer | 6.3yrs | geen gegevens | geen gegevens |
12.8yrs
Gemiddelde duur
Ervaren management: Het managementteam van TGTX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 12.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 12.8yrs | US$15.84m | 5.72% $ 200.9m | |
| Lead Independent Director | 12.5yrs | US$304.70k | 0.17% $ 5.8m | |
| Independent Director | 9.8yrs | US$264.70k | 0.18% $ 6.5m | |
| Independent Director | 11.9yrs | US$262.20k | 0.17% $ 6.0m | |
| Independent Director | 4.5yrs | US$259.70k | 0.073% $ 2.6m | |
| Independent Director | 9.3yrs | US$262.20k | 0.17% $ 5.9m |
10.9yrs
Gemiddelde duur
58.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TGTX zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.9 jaar).